Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.*

The core requirement for Schedule II prescriptions via telemedicine was reversed: the introduced bill stated no in-person exam was required (only real-time audio/video needed), while the ACS now requires an initial in-person examination plus subsequent in-person visits every three months for the duration of the prescription.

New paragraph (4) establishes a specific framework for stimulant prescriptions to adults: the initial exam may be in-person or via telehealth, but if telehealth is used, an in-person visit is required within 30 days. Subsequent contacts are required every three months (in-person or telehealth), with at least one in-person visit annually.

New paragraph (5) adds a general requirement that all Schedule II prescriptions via telemedicine must use interactive real-time two-way audio and visual technologies, consistent with state and federal law, and meet the same standard of care as in-person settings.

New paragraph (3) creates exceptions to the in-person requirement for: patients in active cancer treatment, receiving hospice or palliative care, long-term care facility residents; patients undergoing evaluation or treatment related to P.L.2019 c.59 (mental health services); and medications prescribed for substance use disorder treatment.

The exception for minors under 18 receiving stimulant prescriptions was restructured: it now explicitly references paragraph (1) not applying, and the requirement that the provider be using interactive real-time two-way audio and video was removed from this specific paragraph (now covered by the general paragraph 5 requirement).

The synopsis changed from 'permits prescription without in-person examination' to 'revises certain requirements for prescription,' reflecting the shift from a permissive framework to a structured regulatory one with multiple tiers of requirements and exceptions.